Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CVD 1208S-122 (University of Maryland, Baltimore)
- Development stage
- Unknown
- Lead developer
- University of Maryland, Baltimore
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Oral
01
Overview
CVD 1208S-122 is a live-attenuated, oral vaccine candidate designed to provide broad protection against both *Shigella flexneri* 2a and enterotoxigenic *Escherichia coli* (ETEC). Developed by the Center for Vaccine Development (CVD) at the University of Maryland, Baltimore, the vaccine utilizes an attenuated *S. flexneri* 2a strain (CVD 1208S) as a live vector. This vector is genetically engineered to express key ETEC antigens, specifically the colonization factor antigen I (CFA/I) and the B subunit of the heat-labile enterotoxin (LTB). By mimicking a natural infection without causing disease, the vaccine aims to stimulate mucosal and systemic immunity in the gastrointestinal tract, targeting the primary bacterial causes of moderate-to-severe diarrhea in children in developing countries and travelers.
- Other names
- CVD 1208S-122 Shigella-ETEC VaccineCVD1208S-122 Shigella-ETEC VaccineCVD-1208S-122 Shigella-ETEC Vaccine
02
Targets
Host B-cell receptors specific for CFA/I fimbrial antigensHost B-cell receptors specific for Shigella flexneri 2a O-antigen and outer membrane antigensGM1 (GM1 ganglioside)
Beyond the preview
Go deeper on CVD 1208S-122 (University of Maryland, Baltimore).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CVD 1208S-122 (University of Maryland, Baltimore).